ALDER BIOPHARMACEUTICALS INC 4/A
4/A · ALDER BIOPHARMACEUTICALS INC · Filed May 21, 2015
Insider Transaction Report
Form 4/AAmended
DOW STEPHEN M
Director
Transactions
- Sale
Common Stock
2015-05-20$40.39/sh−8,462$341,820→ 4,313,992 total(indirect: See Footnote) - Award
Stock Option (Right To Buy)
2015-05-19+6,350→ 6,350 totalExercise: $39.66Exp: 2025-05-18→ Common Stock (6,350 underlying)
Footnotes (6)
- [F1]This Form 4 Amendment is being filed to replace in total the Form 4 filed earlier today on behalf of Steve Dow for Alder BioPharmaceuticals, Inc. An incorrect CIK code was used which resulted in the error.
- [F2]Represents 8,462 Common Shares sold directly by Sevin Rosen Bayless Management Company ("SRBMC") pursuant to Rule 144 under the Securities Act of 1933, as amended.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.7025, inclusive. Information can be provided to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]Total Common Shares of 4,313,992 represents 3,947,770 shares owned directly by Sevin Rosen Fund IX L.P., ("SRFIX"), 101,104 shares owned directly by Sevin Rosen IX Affiliates Fund L.P. ("SRIX AFF") and 265,118 shares owned directly by The Dow Family Trust the ("Dow Trust"). Reporting person is a member of the general partner of SRFIX and SRIX AFF, and as a member is deemed to have shared voting and dispositive power of the shares held by SRFIX and SRIX AFF, and disclaims beneficial ownership except to the extent of his proportionate interest in these shares. Reporting person is a director of SRBMC and is deemed to have shared voting and dispositive power of these shares and disclaims beneficial ownership with no pecuniary interest in these shares. Reporting person is a trustee of the Dow Trust.
- [F5]This option was issued to the reporting person pursuant to the Issuer's 2014 Equity Incentive Plan and is effective immediately following the Issuer's Annual Meeting of Stockholders.
- [F6]Options fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.